2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group.
Still, being a Dividend King does not make a company immune to challenges. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. But these longtime dividend payers remain excellent stocks to buy on the dip. Here's why.
Source Fool.com
Abbott Laboratories Aktie
102,16 €
4,46 %
Die Abbott Laboratories Aktie erhält starke Unterstützung mit mehreren Buy- und keiner Sell-Einschätzung.
Ein positives Kurspotenzial für Abbott Laboratories ist gegeben, mit einem Kursziel von 116 € über dem aktuellen Kurs von 102.16 €.
